By: IPP Bureau
Last updated : October 07, 2025 5:58 pm
Celonic Group, one of the leading “pureplay” Biologics CDMO, and the Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution.
The alliance combines Celonic’s advanced biologics capabilities with Carbogen Amcis’ expertise in payload synthesis, conjugation, and sterile fill-finish, creating a seamless, end-to-end platform for ADC innovators.
This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and Carbogen Amcis aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.
“This strategic alliance is a direct response to the evolving needs of ADC innovators,” said Dr. Samanta Cimitan, CEO of Celonic Group. “By integrating Celonic’s advanced biologics platforms with Carbogen Amcis’s world-class payload and conjugation capabilities, we’re enabling a fully harmonised development and manufacturing pathway, from DNA to drug product. It’s a scalable, compliant, and commercially ready solution designed to accelerate innovation and reduce complexity for our partners.”
Celonic Group recently expanded its Biologics Development Center in Basel and GMP manufacturing site in Heidelberg, adding high-yield GS-CHOvolution™ cell line platform, enhanced perfusion-based technologies for process optimization to improve productivity, and commercial-scale biomanufacturing suites.
Carbogen Amcis delivered its first ADC project in 2005 and has since supported numerous ADC programs across payload, linker, conjugation, and sterile drug product – giving innovators a single accountable partner from early development through market supply.
“The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility,” said Stephan Fritschi, CEO of Carbogen Amcis Group. “Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant.”
“For more than 2 decades now we’ve been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies, precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end‑to‑end ADC path—from cell line to commercial fill‑finish—under one coordinated platform,” adds Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group.